James F. McDonough
Of Counsel
732-568-8360 jmcdonough@sh-law.comFirm Insights
Possible Pfizer inversion raises questions among lawmakers
Author: James F. McDonough
Date: May 16, 2014
Key Contacts
Back
U.S.-based pharmaceutical company Pfizer has offered to buy British competitor AstraZeneca for $99 billion, according to The New York Times. In buying the company and moving its headquarters to Britain, Pfizer could avoid U.S. corporate tax liability on its income outside of the the country. Currently, the company pays an effective tax rate of approximately 27 percent – much higher than the British corporate income tax rate of 21 percent.
There are at least 50 American companies that have undergone the controversial inversion process, in which a U.S. company merges with a smaller foreign company in order to enjoy lower tax rates, almost half of which have occurred in the last two years, according to the news source. If successful, however, Pfizer would be the largest and best-known company to do so.
“Pfizer is the Coca-Cola of health care. It’s as American as apple pie,” Mark Schoenebaum, an analyst with the ISI Group, told the news source. “If there is a deal that is going to start a real dialogue in Washington, it might be a company like this.”
Such a move would result in the loss of tax income from the company for the U.S. government, which amounted to about $2.87 billion last year, Reuters reported. This has sparked serious concern from American lawmakers on both sides of the aisle.
“This further demonstrates the urgency for tax reform,” a spokeswoman for Democratic Sen. Ron Wyden, chairman of the tax-writing U.S. Senate Finance Committee, told the news source. “Now is the time to undertake comprehensive reform to ensure our country stays competitive on a global stage and continues to be the best place for corporate investment.”
The Obama administration included a proposal in its 2015 budget to more seriously regulate deals like the one that Pfizer is attempting, according to Reuters. With Congress deadlocked on tax issues, however, the proposal is unlikely to gain any real ground.
No Aspect of the advertisement has been approved by the Supreme Court. Results may vary depending on your particular facts and legal circumstances.
Related Posts
See all
Does Your Homeowners Insurance Provide Adequate Coverage?
Your home is likely your greatest asset, which is why it is so important to adequately protect it. Homeowners insurance protects you from the financial costs of unforeseen losses, such as theft, fire, and natural disasters, by helping you rebuild and replace possessions that were lost While the definition of “adequate” coverage depends upon a […]
Author: Jesse M. Dimitro
Understanding the Importance of a Non-Contingent Offer
Making a non-contingent offer can dramatically increase your chances of securing a real estate transaction, particularly in competitive markets like New York City. However, buyers should understand that waiving contingencies, including those related to financing, or appraisals, also comes with significant risks. Determining your best strategy requires careful analysis of the property, the market, and […]
Author: Jesse M. Dimitro
Fred D. Zemel Appointed Chair of Strategic Planning at Scarinci & Hollenbeck, LLC
Business Transactional Attorney Zemel to Spearhead Strategic Initiatives for Continued Growth and Innovation Little Falls, NJ – February 21, 2025 – Scarinci & Hollenbeck, LLC is pleased to announce that Partner Fred D. Zemel has been named Chair of the firm’s Strategic Planning Committee. In this role, Mr. Zemel will lead the committee in identifying, […]
Author: Scarinci Hollenbeck, LLC
Novation Agreement Process: Step-by-Step Guide for Businesses
Big changes sometimes occur during the life cycle of a contract. Cancelling a contract outright can be bad for your reputation and your bottom line. Businesses need to know how to best address a change in circumstances, while also protecting their legal rights. One option is to transfer the “benefits and the burdens” of a […]
Author: Dan Brecher
What Is a Trade Secret? Key Elements and Legal Protections Explained
What is a trade secret and why you you protect them? Technology has made trade secret theft even easier and more prevalent. In fact, businesses lose billions of dollars every year due to trade secret theft committed by employees, competitors, and even foreign governments. But what is a trade secret? And how do you protect […]
Author: Ronald S. Bienstock
What Is Title Insurance? Safeguarding Against Title Defects
If you are considering the purchase of a property, you may wonder — what is title insurance, do I need it, and why do I need it? Even seasoned property owners may question if the added expense and extra paperwork is really necessary, especially considering that people and entities insured by title insurance make fewer […]
Author: Patrick T. Conlon
No Aspect of the advertisement has been approved by the Supreme Court. Results may vary depending on your particular facts and legal circumstances.
Sign up to get the latest from our attorneys!
Explore What Matters Most to You.
Consider subscribing to our Firm Insights mailing list by clicking the button below so you can keep up to date with the firm`s latest articles covering various legal topics.
Stay informed and inspired with the latest updates, insights, and events from Scarinci Hollenbeck. Our resource library provides valuable content across a range of categories to keep you connected and ahead of the curve.
Possible Pfizer inversion raises questions among lawmakers
Author: James F. McDonough
U.S.-based pharmaceutical company Pfizer has offered to buy British competitor AstraZeneca for $99 billion, according to The New York Times. In buying the company and moving its headquarters to Britain, Pfizer could avoid U.S. corporate tax liability on its income outside of the the country. Currently, the company pays an effective tax rate of approximately 27 percent – much higher than the British corporate income tax rate of 21 percent.
There are at least 50 American companies that have undergone the controversial inversion process, in which a U.S. company merges with a smaller foreign company in order to enjoy lower tax rates, almost half of which have occurred in the last two years, according to the news source. If successful, however, Pfizer would be the largest and best-known company to do so.
“Pfizer is the Coca-Cola of health care. It’s as American as apple pie,” Mark Schoenebaum, an analyst with the ISI Group, told the news source. “If there is a deal that is going to start a real dialogue in Washington, it might be a company like this.”
Such a move would result in the loss of tax income from the company for the U.S. government, which amounted to about $2.87 billion last year, Reuters reported. This has sparked serious concern from American lawmakers on both sides of the aisle.
“This further demonstrates the urgency for tax reform,” a spokeswoman for Democratic Sen. Ron Wyden, chairman of the tax-writing U.S. Senate Finance Committee, told the news source. “Now is the time to undertake comprehensive reform to ensure our country stays competitive on a global stage and continues to be the best place for corporate investment.”
The Obama administration included a proposal in its 2015 budget to more seriously regulate deals like the one that Pfizer is attempting, according to Reuters. With Congress deadlocked on tax issues, however, the proposal is unlikely to gain any real ground.